DK2717914T3 - Depotformuleringer til administration af proteiner til øjet og fremgangsmåder til fremstilling deraf - Google Patents

Depotformuleringer til administration af proteiner til øjet og fremgangsmåder til fremstilling deraf Download PDF

Info

Publication number
DK2717914T3
DK2717914T3 DK12829655.5T DK12829655T DK2717914T3 DK 2717914 T3 DK2717914 T3 DK 2717914T3 DK 12829655 T DK12829655 T DK 12829655T DK 2717914 T3 DK2717914 T3 DK 2717914T3
Authority
DK
Denmark
Prior art keywords
administration
eye
protein
procedures
producing
Prior art date
Application number
DK12829655.5T
Other languages
English (en)
Inventor
Vernon Wong
Louis Wood
Glenn Huang
Original Assignee
Ramscor Inc
Icon Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor Inc, Icon Bioscience Inc filed Critical Ramscor Inc
Application granted granted Critical
Publication of DK2717914T3 publication Critical patent/DK2717914T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK12829655.5T 2011-06-10 2012-06-11 Depotformuleringer til administration af proteiner til øjet og fremgangsmåder til fremstilling deraf DK2717914T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (1)

Publication Number Publication Date
DK2717914T3 true DK2717914T3 (da) 2020-01-20

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12829655.5T DK2717914T3 (da) 2011-06-10 2012-06-11 Depotformuleringer til administration af proteiner til øjet og fremgangsmåder til fremstilling deraf

Country Status (21)

Country Link
US (1) US9814773B2 (da)
EP (1) EP2717914B1 (da)
JP (1) JP6339011B2 (da)
KR (1) KR20140060274A (da)
CN (1) CN103945865B (da)
AU (1) AU2012304909B2 (da)
BR (1) BR112013031685B1 (da)
CA (1) CA2838289C (da)
CY (1) CY1122771T1 (da)
DK (1) DK2717914T3 (da)
ES (1) ES2761340T3 (da)
HR (1) HRP20192276T1 (da)
HU (1) HUE047737T2 (da)
IN (1) IN2013MN02384A (da)
LT (1) LT2717914T (da)
MX (1) MX359119B (da)
PL (1) PL2717914T3 (da)
PT (1) PT2717914T (da)
RS (1) RS60051B1 (da)
SI (1) SI2717914T1 (da)
WO (1) WO2013036309A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014268434B2 (en) * 2013-05-24 2018-11-22 Icon Bioscience, Inc. Use of sustained release dexamethasone in post-cataract surgery inflammation
AU2015257651B2 (en) * 2014-05-08 2020-01-23 Panoptes Pharma Ges.M.B.H. Compounds for treating ophthalmic diseases and disorders
RU2704813C2 (ru) 2015-03-18 2019-10-31 Сантен Фармасьютикал Ко., Лтд. Фармацевтическая композиция с пролонгированным высвобождением
CA2991015A1 (en) * 2015-07-01 2017-01-05 Santen Pharmaceutical Co., Ltd. Depot preparation containing citric acid ester
HUE052832T2 (hu) * 2015-08-03 2021-05-28 Tolmar International Ltd Folyékony polimer leadó rendszer gyógyszerek nyújtott adagolására
EA201890788A1 (ru) 2015-09-21 2018-09-28 Тева Фармасьютикалз Интернэшнл Гмбх Препараты оланзапина с замедленным высвобождением
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
CN111757764B (zh) 2018-02-09 2022-09-06 爱康生物科学股份有限公司 用于从注射器装载和输送小体积剂量的系统、套件和方法
CN112423740A (zh) 2018-05-01 2021-02-26 奇比有限公司 用于将药物持续递送至视网膜的滴眼剂制剂和方法
CA3097927A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
US11439685B2 (en) 2020-05-22 2022-09-13 Trustees Of Boston University Formulations for treating a fibrotic disease
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
EP1299048A4 (en) * 2000-06-28 2005-09-28 Atul J Shukla BIODEGRADABLE VEHICLES AND SYSTEMS FOR DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050079202A1 (en) * 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
CA2582096C (en) * 2004-10-01 2014-01-07 Ramscor, Inc. Conveniently implantable sustained release drug compositions
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
ES2672806T3 (es) * 2009-07-03 2018-06-18 Armbruster Biotechnology Gmbh Injerto óseo y material biocompuesto

Also Published As

Publication number Publication date
PL2717914T3 (pl) 2020-05-18
EP2717914B1 (en) 2019-10-30
WO2013036309A2 (en) 2013-03-14
CA2838289C (en) 2019-09-10
MX359119B (es) 2018-09-14
LT2717914T (lt) 2020-03-25
US20140140992A1 (en) 2014-05-22
WO2013036309A3 (en) 2013-05-10
NZ619707A (en) 2015-01-30
MX2013014461A (es) 2014-05-14
CY1122771T1 (el) 2021-05-05
CN103945865A (zh) 2014-07-23
AU2012304909B2 (en) 2017-06-08
SI2717914T1 (sl) 2020-07-31
CN103945865B (zh) 2016-10-26
CA2838289A1 (en) 2013-03-14
BR112013031685A2 (pt) 2017-02-07
EP2717914A2 (en) 2014-04-16
HUE047737T2 (hu) 2020-05-28
IN2013MN02384A (da) 2015-06-12
KR20140060274A (ko) 2014-05-19
RS60051B1 (sr) 2020-04-30
US9814773B2 (en) 2017-11-14
JP6339011B2 (ja) 2018-06-06
EP2717914A4 (en) 2015-05-13
AU2012304909A1 (en) 2013-12-19
HRP20192276T1 (hr) 2020-05-15
PT2717914T (pt) 2019-12-18
JP2014516087A (ja) 2014-07-07
ES2761340T3 (es) 2020-05-19
BR112013031685B1 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
DK2717914T3 (da) Depotformuleringer til administration af proteiner til øjet og fremgangsmåder til fremstilling deraf
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
SMT201600464B (it) Procedimento per la preparazione di esterolo
DK3321276T3 (da) Fusionsproteiner til behandling af metaboliske lidelser
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK3068392T3 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
DK3130347T3 (da) PH20-polypeptidvarianter, formuleringer og anvendelser deraf
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3091029T3 (da) Anti-IL13-antistofformuleringer
DK3378862T3 (da) Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
DK2771364T3 (da) Fremstilling af heterodimere proteiner
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
DK3050972T3 (da) Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider
CO6811815A2 (es) Composiciones de nucleasa terapéuticas y métodos
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK2663864T3 (da) Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
DK2917358T3 (da) Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater
DK3603704T3 (da) Indgivelse af medikament
CO6900117A2 (es) Formulaciones peptídicas de liberación controlada